文献速递消化系统肿瘤

免疫检查点抑制剂二线及后线治疗微卫星不稳定转移性结直肠癌的疗效:采用合成对照臂的非随机评估

Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
PubMed 文献 · Eur J Cancer · 2024-01-15

本研究利用NIPICOL与CheckMate 142两项Ⅱ期试验中176例接受免疫检查点抑制剂(ICI)治疗的微卫星不稳定(MSI)转移性结直肠癌(mCRC)患者个体数据,并以ARCAD数据库中4026例二线及后线非ICI历史随机对照试验患者为对照,通过患者自身前后对照(生长调节指数GMI)及匹配比较评估ICI疗效。结果显示ICI组中位无进展生存期32.66个月,既往治疗为4.07个月,中位GMI为4.97(HR=0.16,95%CI 0.11-0.22,P<0.001);与匹配的非ICI患者相比,三线及二线ICI组中位总生存期均未达到,各对照亚组HR在0.10至0.30之间。

要点

  • ICI治疗MSI mCRC患者的中位无进展生存期为32.66个月,既往治疗为4.07个月,中位GMI为4.97(HR=0.16,95%CI 0.11-0.22,P<0.001)。
  • 三线ICI组中位总生存期未达到,优于安慰剂组3.52个月(HR=0.20,95%CI 0.10-0.41,P<0.001)和活性药物组6.51个月(HR=0.30,95%CI 0.15-0.60,P=0.001)。
  • 二线ICI组中位总生存期未达到,优于化疗+安慰剂组11.7个月(HR=0.12,95%CI 0.07-0.22,P<0.001)和化疗+靶向治疗组16.3个月(HR=0.10,95%CI 0.05-0.19,P<0.001)。

核心结论

  • ICI对二线及后线的MSI mCRC患者显示出较高的效应量。
  • 本工作或可作为方法学示例,在实验性治疗获益可能较高时避免开展随机对照试验。

研究设计与样本

  • 分析NIPICOL和CheckMate 142两项Ⅱ期试验中接受ICI联合治疗的MSI mCRC患者个体数据(N=176)。
  • 对照为五项二线或后线非ICI mCRC历史随机对照试验(N=4026),取自ARCAD数据库。
  • 首先基于生长调节指数(GMI,即ICI治疗与前一線治疗的无进展生存期比值)进行患者自身对照,再将ICI治疗患者与ARCAD数据库历史随机对照试验中匹配的非ICI治疗患者比较生存结局。

主要发现

  • ICI治疗患者中位无进展生存期为32.66个月(范围0.10-74.25),既往治疗为4.07个月(范围0.7-49.87),中位GMI为4.97(范围0.07-59.51;HR=0.16,95%CI 0.11-0.22,P<0.001)。
  • 三线治疗中,ICI组中位总生存期未达到,安慰剂组为3.52个月(HR=0.20,95%CI 0.10-0.41,P<0.001),活性药物组为6.51个月(HR=0.30,95%CI 0.15-0.60,P=0.001)。
  • 二线治疗中,ICI组中位总生存期未达到,化疗+安慰剂组为11.7个月(HR=0.12,95%CI 0.07-0.22,P<0.001),化疗+靶向治疗组为16.3个月(HR=0.10,95%CI 0.05-0.19,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors (ICIs) appeared active in single-arm trials for patients with chemoresistant metastatic colorectal cancer (mCRC) harboring microsatellite instability (MSI). Given the paucity of randomised controlled trials (RCTs) in this setting, we evaluated the effect size of ICIs using intra-patients comparison and ARCAD database as historical controls. PATIENTS AND METHODS: Individual-patient data from NIPICOL and CheckMate 142 phase II trials that evaluated a combination of ICIs for MSI mCRC patients (N = 176) and from five non-ICI mCRC historical RCTs in second-line or latter (N = 4026) were analyzed. Firstly, promising of ICIs was identified using intra-patient comparison based on growth modulation index (GMI) defined the ratio of progression-free survivals (PFS) on ICIs and previous line of therapy. Survival outcomes of ICIs-treated patients were then compared with those matched non-ICIs treated from ARCAD database historical RCTs. RESULTS: Among ICIs-treated patients, median PFS on ICIs was 32.66 (range 0.10-74.25) versus 4.07 months (range 0.7-49.87) on prior therapy, resulting on median GMI of 4.97 (range 0.07-59.51; hazard-ratio (HR)= 0.16 (95 %CI=0.11-0.22, P < 0.001)). Compared to matched non-ICI patients, in third-line, median overall survival (OS) was not reached with ICIs versus 3.52 months with placebo (HR=0.20, 95 %CI=0.10-0.41, P < 0.001), and 6.51 months with active drugs (HR=0.30, 95 %CI=0.15-0.60, P = 0.001). In second-line, median OS was not reached with ICIs versus 11.7 months with chemotherapy+placebo (HR=0.12, 95 %CI=0.07-0.22, P < 0.001), and 16.3 months with chemotherapy+targeted therapy (HR=0.10, 95 %CI=0.05-0.19, P < 0.001). CONCLUSION: ICIs demonstrates high effect size for MSI mCRC patients in second-line and later. This work might be useful as an example of methodology to avoid RCTs when benefit from experimental therapy is likely to be high.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cohen R, Raeisi M, Chibaudel B, et al. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer. 2024. PMID: 38241818. doi:10.1016/j.ejca.2024.113537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。